TCL Archive NCAB Asks For Cost Reimbursement n Patients In Clinical Trials Until More Data Available October 5, 1984
TCL Archive FDA unlikely to pull Iressa from market. Iressa a case study in how not to develop a drug, ODAC member says. April 1, 2005
TCL Archive Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says. May 7, 2004
TCL Archive House Committee Hits “Earmarks” For diseases; Broder Is Lectured On Occupational Exposures May 21, 1993
